MAIA
Daratumumab + Lenalidomide/Dex in Transplant-Ineligible Myeloma
Patient / Population Intervention / Exposition Comparaison Critère de jugement
In 737 patients with newly diagnosed transplant-ineligible multiple myeloma, daratumumab + lenalidomide + dexamethasone improved progression-free and overall survival compared with lenalidomide + dexamethasone.
N
737
Schéma
Open-label RCT
Critère
Progression-free survival
Pertinence
2
RésultatPFS HR 0.56. MRD-negative 24.2% vs 7.3%. 5-yr OS 66.3% vs 53.1% (HR 0.68).
Facon T, et al. N Engl J Med. 2019;380(22):2104-2115; Facon T, et al. Lancet Oncol. 2021;22(11):1582-1596. 10.1056/NEJMoa1817249
Discussion et critique
Established anti-CD38 in front-line myeloma for patients ineligible for transplant. The principle has since been extended to transplant-eligible disease.